Related references
Note: Only part of the references are listed.Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
Laurent Arnaud et al.
AUTOIMMUNITY REVIEWS (2015)
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant
Vittorio Pengo et al.
THROMBOSIS RESEARCH (2015)
Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study
S. Liao et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study
P. Mustonen et al.
LUPUS (2014)
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study
Amelia Ruffatti et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Vittorio Pengo et al.
BLOOD (2011)
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
G. Ruiz-Irastorza et al.
LUPUS (2011)
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
V. Pengo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
A. Ruffatti et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
T. Hereng et al.
LUPUS (2008)
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome - A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals
Doruk Erkan et al.
ARTHRITIS AND RHEUMATISM (2007)
Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: A 5-year follow-up
Tunde Tarr et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2007)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis
R Forastiero et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis
B de Laat et al.
BLOOD (2005)
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
M Galli et al.
BLOOD (2003)
Epidemiology of the antiphospholipid antibody syndrome
M Petri
JOURNAL OF AUTOIMMUNITY (2000)
Share Paper
